Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment

Overview of attention for article published in The Journal of Headache and Pain, September 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

news: 5 news outlets
policy: 1 policy source

twitter: 1 X user

Citations

dimensions_citation: 29 Dimensions

Readers on

mendeley: 40 Mendeley

Summary News Policy documents X Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

Erenumab for preventing migraine : Final appraisal determination committee papers

Cited by National Institute for Health and Care Excellence on 19 Sep 2019

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.